Dae Gon Ha

After the release of Ophthotech Corp (NASDAQ: OPHT)'s fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration. The Disappointment The company announced disappointing...

Leerink analysts Joseph Schwartz and Dae Gon Ha are confident that Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) will gain from MPS 7 treatment ahead of pivotal data. The two analysts boosted their price target to $85 from $80 while rating the stock at Outperform. The brokerage listed four main...